[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353241-105":59,"doc-detail-353241-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cdo1-is-a-new-biomarker-to-discriminate-aggressive-forms-of-prostate-cancer","CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer","","Prostate cancer remains challenging to predict for recurrence after initial treatment, limiting timely therapeutic decisions at biopsy stage. This study identifies cysteine dioxygenase CDO1 as a predictive biomarker in prostate cancer progression. Transcriptomic results show reduced CDO1 expression in relapsed patients and worse survival. CDO1 regulation links to methylation and androgen signaling, while CDO1 inhibition increases migration and non-adherent growth and reveals roles in endoplasmic reticulum stress and protein unfolding.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cdo1-is-a-new-biomarker-to-discriminate-aggressive-forms-of-prostate-cancer/353241/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cdo1-is-a-new-biomarker-to-discriminate-aggressive-forms-of-prostate-cancer/353241.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CDO1 considered important in prostate cancer recurrence risk prediction?","Question",{"text":112,"@type":113},"The study shows CDO1 expression is significantly reduced in patients who relapsed, and lower CDO1 correlates with poorer survival, supporting its predictive value for progression and recurrence risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How might CDO1 expression be regulated in prostate cancer?",{"text":117,"@type":113},"In prostate cancer, CDO1 expression is described as potentially regulated by methylation and the androgen signaling pathway.",{"name":119,"@type":110,"acceptedAnswer":120},"What happens in prostate cancer cells when CDO1 expression is inhibited?",{"text":121,"@type":113},"Inhibition of CDO1 in VCaP cells increases cell migration and non-adherent growth, indicating a functional role in aggressiveness and tumor-related behaviors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353241,1791162436,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nCDO1 is a new biomarker to discriminate aggressive forms of prostate cancer  \nJeanne Gaspar Lopes 1,2, Angel Markovic1,2, Cécile M Champy1,3, Nicolas Aubourg2, Jacques RR Mathieu 4, Federica Alberti 1, Pascale Soyeux-Porte1,2, Kadiatou Drame 1, Marine Louarn 2, Thibaud Jamet 1,2, Romain Huc1,5, Alexandre de la Taille 1,2,3, Charles-Antoine Dutertre2,6, Damien Destouches1,2, Francis Vacherot1,2 and Virginie Firlej 1,2 ✉  \n© The Author(s) 2026  \nWorldwide, prostate cancer (PCa) ranks second in terms of incidence and eighth in terms of mortality. While most cancers remain silent after initial treatment, some tumors recur. At present, we are unable to predict which patients are at risk of recurrence. In order to determine this risk of recurrence as early as at the biopsy stage, and to enable better therapeutic management of patients, it is essential to identify new biomarkers. In this study, we have demonstrated that Cysteine Dioxygenase CDO1 could be a predictive marker in PCa progression. Transcriptomic analysis showed that CDO1 expression is signiﬁcantly reduced in patients who have relapsed and lower CDO1 expression is associated with poorer survival outcomes. In PCa, CDO1 expression could be regulated by methylation and androgen signaling pathway. Furthermore, inhibition of CDO1 expression in VCaP prostate cancer cells led to increased cell migration and non-adherent growth. Finally, transcriptomic analysis of these cells with inhibited CDO1 expression demonstrates the complex role of CDO1 and its possible involvement in the mechanisms regulating endoplasmic reticulum stress and protein unfolding. Altogether, these results describe the loss of CDO1 as a marker of aggressiveness in PCa. Furthermore, the loss of CDO1 is thought to be responsible for tumor progression in vitro by acting on multiple signaling pathways.  \nOncogene (2026) 45:2795–2807; [https://doi.org/10.1038/s41388-026-03842-5](https://doi.org/10.1038/s41388-026-03842-5)  \nINTRODUCTION  \nProstate cancer (PCa) is worldwide the second leading cancer in men and ranks eighth in terms of mortality [1] . While most PCa progress favorably after radiotherapy or radical surgery, 20% of patients will experience recurrence. At this stage, patients will be treated by androgen deprivation therapy (ADT) in combination or not with second-generation hormone therapies. However, resistance to these treatments inevitably develops, leading to metastatic disease and ultimately a fatal outcome. Currently, there is no early test available to guide treatment. Therapeutic strategies are primarily based on the ISUP score, MRI, and PSA level. However, in some cases, patient outcome seems to be independent of the stage and/or the Gleason score which indicates the degree of aggressiveness of the cancer. Thus, it is still impossible to distinguish relapsing and non-relapsing disease. Precise and effective markers would therefore enable us to differentiate those two forms, to better adapt management and avoid any over-treatment that could lead to signiﬁcant side effects.  \nCysteine dioxygenase type 1 (CDO1) is a cytosolic enzyme involved in taurine biosynthesis and in the regulation of cysteine concentration [2] . In physiological condition, this non-heme iron metalloenzyme catalyses the reaction of L-cysteine to cysteinesulfonic acid (CSA) in the presence of oxygen. CSA can then be  \nconverted to hypotaurine to form taurine, or to 3-sulﬁnylpyruvate to form pyruvate preventing from cysteine accumulation. Defective CDO1 activity is associated with cytotoxicity and neurotoxicity and plays a role in inﬂammatory (rheumatoid arthritis) and neurodegenerative (Parkinson’s and Alzheimer’s disease) diseases [3] . CDO-/-mice present elevated cysteine levels. In this case, cysteine is metabolized via CDO1-independent pathways. Nevertheless, an excessive increase in H2S/HS- production is observed in tissues, leading to cytotoxicity, parti","cbCaihje9B7MZbNM","https://ap.wps.com/l/cbCaihje9B7MZbNM","pdf",4425564,13,"English","# Introduction\n## CDO1 biology and cancer relevance\n## Need for early biomarkers in prostate cancer","[{\"question\":\"Why is CDO1 considered important in prostate cancer recurrence risk prediction?\",\"answer\":\"The study shows CDO1 expression is significantly reduced in patients who relapsed, and lower CDO1 correlates with poorer survival, supporting its predictive value for progression and recurrence risk.\"},{\"question\":\"How might CDO1 expression be regulated in prostate cancer?\",\"answer\":\"In prostate cancer, CDO1 expression is described as potentially regulated by methylation and the androgen signaling pathway.\"},{\"question\":\"What happens in prostate cancer cells when CDO1 expression is inhibited?\",\"answer\":\"Inhibition of CDO1 in VCaP cells increases cell migration and non-adherent growth, indicating a functional role in aggressiveness and tumor-related behaviors.\"}]","CDO1 is a new biomarker to discriminate aggressive forms of prostate cancer | PDF",1790103819,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79af2f3343703d387076ef410ca59556.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52ac37bfcb4495de2ca40eb4ab1ef3ee.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d847704c62fb1d997fd86feb94569577.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/247c528c0967b8359abc8fc725436d91.webp",980,1301]